Comparing AEterna Zentaris (AEZS) and Its Peers
AEterna Zentaris (NASDAQ: AEZS) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare AEterna Zentaris to similar companies based on the strength of its profitability, dividends, earnings, valuation, analyst recommendations, risk and institutional ownership.
This table compares AEterna Zentaris and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AEterna Zentaris Competitors||-3,679.23%||-415.77%||-47.88%|
This is a summary of recent ratings and target prices for AEterna Zentaris and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AEterna Zentaris Competitors||788||2943||6420||144||2.58|
AEterna Zentaris currently has a consensus target price of $4.33, indicating a potential upside of 103.44%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.27%. Given AEterna Zentaris’ stronger consensus rating and higher probable upside, research analysts plainly believe AEterna Zentaris is more favorable than its competitors.
Institutional & Insider Ownership
2.9% of AEterna Zentaris shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares AEterna Zentaris and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|AEterna Zentaris||$1.08 million||-$27.36 million||-1.18|
|AEterna Zentaris Competitors||$207.53 million||-$2.40 million||0.00|
AEterna Zentaris’ competitors have higher revenue and earnings than AEterna Zentaris. AEterna Zentaris is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
AEterna Zentaris has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, AEterna Zentaris’ competitors have a beta of 1.67, meaning that their average share price is 67% more volatile than the S&P 500.
AEterna Zentaris competitors beat AEterna Zentaris on 8 of the 12 factors compared.
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company’s principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company’s direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.